Phase 1 Trial of Allogeneic Gene-Modified Tumor Cell Vaccine RCC-26/CD80/IL-2 in Patients With Metastatic Renal Cell Carcinoma

Human Gene Therapy - United States
doi 10.1089/hum.2008.192
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Mary Ann Liebert Inc

Related search

Disparities in the Treatment of Patients With IL-2 for Metastatic Renal Cell Carcinoma

Urologic Oncology: Seminars and Original Investigations
OncologyUrology
2010English

A Phase 2 Trial of Sunitinib in Patients With Advanced Non–clear Cell Renal Cell Carcinoma

European Urology
Urology
2012English

Durability of Responses in Patients With Metastatic Renal Cell Carcinoma Treated With High Dose Interleukin-2 (HD IL-2)

Journal for ImmunoTherapy of Cancer
OncologyMolecular MedicinePharmacologyCancer ResearchAllergyImmunology
2015English

Phase I Trial of Sunitinib and Temsirolimus in Metastatic Renal Cell Carcinoma

Clinical Genitourinary Cancer
OncologyUrology
2015English

A Phase I/Ii Trial of BNC105P With Everolimus in Metastatic Renal Cell Carcinoma

Clinical Cancer Research
Cancer ResearchOncology
2015English

Phase II Trial of Capecitabine and Weekly Docetaxel in Metastatic Renal Cell Carcinoma

Urology
Urology
2008English

Clinical and Immunologic Effects of Intranodal Autologous Tumor Lysate-Dendritic Cell Vaccine With Aldesleukin (Interleukin 2) and IFN- 2a Therapy in Metastatic Renal Cell Carcinoma Patients

Clinical Cancer Research
Cancer ResearchOncology
2009English

Phase I Clinical Trial of Human Vascular Endothelial Growth Factor Receptor 1 Peptide Vaccines for Patients With Metastatic Renal Cell Carcinoma

British Journal of Cancer
Cancer ResearchOncology
2013English

High-Dose Interleukin 2 in Patients With Metastatic Renal Cell Carcinoma With Sarcomatoid Features

PLoS ONE
Multidisciplinary
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy